Back

Discovering and targeting dynamic drugging pocketsof the oncogene KRAS-G12D

Hu, Z.; Marti, J.

2022-07-02 cancer biology
10.1101/2022.07.01.498403 bioRxiv
Show abstract

Activated KRAS-G12D mutations are the one of most frequent oncogenic drivers in human cancers. Unfortunately, no therapeutic agent directly targeting KRAS-G12D has been clinically approved yet, with such mutated species remaining undrugged. Notably, cofactor Mg2+ is closely related to the function of small GTPases, but no investigation has been done yet on Mg2+ when associated with KRAS. Herein, through microsecond scale molecular dynamics simulations we have found that Mg2+ plays a crucial role in the conformational changes of the KRAS-GDP complex. We have located two brand new druggable dynamic pockets exclusive to KRAS-G12D. Using the structural characteristics of these two dynamic pockets, we designed in silico the inhibitor DBD15-21-22, which can specifically and tightly target KRAS-G12D-GDP-Mg2+ ternary complex and we have verified that DBD15-21-22 is harmless for wild-type KRAS. Overall, we provide two brand new druggable pockets located on KRAS-G12D, as well as suitable strategies for KRAS-G12D inhibition.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.